Efficacy and Safety of Transarterial Chemoembolization and Repeated Partial Splenic Embolization for Hepatocellular Carcinoma with Hypersplenism and Thrombocytopenia.
{"title":"Efficacy and Safety of Transarterial Chemoembolization and Repeated Partial Splenic Embolization for Hepatocellular Carcinoma with Hypersplenism and Thrombocytopenia.","authors":"Wei Hong, Zizhuo Wang, Wei Yao, Xin Zhang, Lijie Zhang, Bin Liang","doi":"10.2147/JHC.S455461","DOIUrl":null,"url":null,"abstract":"<p><strong>Aim: </strong>Partial splenic embolization (PSE) combined with transarterial chemoembolization (TACE) has been reported in treatment of hepatocellular carcinoma (HCC) with cirrhotic hypersplenism and thrombocytopenia. However, efficacy and safety of repeated PSE when required are unclear. This study aims to investigate post-procedural changes in peripheral blood cell and hepatic function, progression-free survival (PFS), and safety of HCC patients with hypersplenism received TACE and repeated PSE compared to those received TACE alone.</p><p><strong>Methods: </strong>This retrospective study included 102 HCC patients with hypersplenism who received TACE (n = 73) or TACE+PSE (n = 29) from January 2014 to December 2021. Changes in peripheral blood cell and hepatic function were investigated at 1 week, 2, 6, 12, 18, and 24 months. TACE procedure sessions and adverse events were recorded. PFS and prognostic factors were analyzed.</p><p><strong>Results: </strong>Despite response to initial PSE being limited, repeated PSE increased platelet (PLT) again, which peaked at 18 months. It also continued to improve red blood cell (RBC) and hemoglobin, which showed significant differences in changes from baseline between two groups until 24 months, as well as Child-Pugh scores at 12 and 18 months. Mean TACE procedure sessions were significantly higher in TACE+PSE group than that in TACE alone group (4.55 vs 3.26, <i>P</i> = 0.019). TACE+PSE group had longer median PFS (19.4 vs 9.5 months, <i>P</i> = 0.023) than TACE alone group, where PSE was an independent protective factor (HR, 0.508; <i>P</i> = 0.014). Initial and repeated PSE showed no significant differences in safety.</p><p><strong>Conclusion: </strong>Repeated PSE is effective in increasing PLT again and improving RBC, hemoglobin and liver function. It contributed to performing serial TACE procedures thereafter. TACE combined with repeated PSE has significantly longer PFS than TACE alone, where PSE was an independent protective factor. Moreover, the safety of repeated PSE was comparable to initial PSE.</p>","PeriodicalId":15906,"journal":{"name":"Journal of Hepatocellular Carcinoma","volume":"11 ","pages":"1065-1078"},"PeriodicalIF":4.2000,"publicationDate":"2024-06-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11179653/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Hepatocellular Carcinoma","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2147/JHC.S455461","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Aim: Partial splenic embolization (PSE) combined with transarterial chemoembolization (TACE) has been reported in treatment of hepatocellular carcinoma (HCC) with cirrhotic hypersplenism and thrombocytopenia. However, efficacy and safety of repeated PSE when required are unclear. This study aims to investigate post-procedural changes in peripheral blood cell and hepatic function, progression-free survival (PFS), and safety of HCC patients with hypersplenism received TACE and repeated PSE compared to those received TACE alone.
Methods: This retrospective study included 102 HCC patients with hypersplenism who received TACE (n = 73) or TACE+PSE (n = 29) from January 2014 to December 2021. Changes in peripheral blood cell and hepatic function were investigated at 1 week, 2, 6, 12, 18, and 24 months. TACE procedure sessions and adverse events were recorded. PFS and prognostic factors were analyzed.
Results: Despite response to initial PSE being limited, repeated PSE increased platelet (PLT) again, which peaked at 18 months. It also continued to improve red blood cell (RBC) and hemoglobin, which showed significant differences in changes from baseline between two groups until 24 months, as well as Child-Pugh scores at 12 and 18 months. Mean TACE procedure sessions were significantly higher in TACE+PSE group than that in TACE alone group (4.55 vs 3.26, P = 0.019). TACE+PSE group had longer median PFS (19.4 vs 9.5 months, P = 0.023) than TACE alone group, where PSE was an independent protective factor (HR, 0.508; P = 0.014). Initial and repeated PSE showed no significant differences in safety.
Conclusion: Repeated PSE is effective in increasing PLT again and improving RBC, hemoglobin and liver function. It contributed to performing serial TACE procedures thereafter. TACE combined with repeated PSE has significantly longer PFS than TACE alone, where PSE was an independent protective factor. Moreover, the safety of repeated PSE was comparable to initial PSE.
目的:部分脾栓塞(PSE)联合经动脉化疗栓塞(TACE)治疗肝细胞癌(HCC)伴肝硬化脾功能亢进和血小板减少症已有报道。然而,在必要时重复 PSE 的有效性和安全性尚不明确。本研究旨在调查接受TACE和重复PSE治疗的脾功能亢进HCC患者与单纯接受TACE治疗的患者术后外周血细胞和肝功能的变化、无进展生存期(PFS)和安全性:这项回顾性研究纳入了2014年1月至2021年12月期间接受TACE(73例)或TACE+PSE(29例)治疗的102例脾功能亢进的HCC患者。研究人员分别在 1 周、2、6、12、18 和 24 个月时调查了外周血细胞和肝功能的变化。记录了 TACE 手术疗程和不良事件。对PFS和预后因素进行了分析:结果:尽管对初次 PSE 的反应有限,但重复 PSE 再次增加了血小板(PLT),并在 18 个月时达到峰值。此外,PSE 还能继续改善红细胞(RBC)和血红蛋白,两组患者在 24 个月前与基线相比的变化有显著差异,Child-Pugh 评分在 12 个月和 18 个月时也有显著差异。TACE+PSE组的平均TACE疗程明显高于单纯TACE组(4.55 vs 3.26,P = 0.019)。TACE+PSE组的中位PFS(19.4个月 vs 9.5个月,P = 0.023)长于单纯TACE组,其中PSE是一个独立的保护因素(HR,0.508;P = 0.014)。首次和重复 PSE 在安全性方面无显著差异:结论:重复 PSE 能有效增加 PLT,改善 RBC、血红蛋白和肝功能。结论:重复 PSE 能有效增加 PLT,改善 RBC、血红蛋白和肝功能,有助于此后进行连续的 TACE 治疗。TACE 联合重复 PSE 的 PFS 明显长于单纯 TACE,其中 PSE 是一个独立的保护因素。此外,重复 PSE 的安全性与初始 PSE 相当。